X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
cancer (4) 4
humans (4) 4
index medicus (4) 4
middle aged (4) 4
adult (3) 3
aged (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
chemotherapy (3) 3
disease-free survival (3) 3
female (3) 3
hematology, oncology and palliative medicine (3) 3
male (3) 3
oncology (3) 3
research (3) 3
treatment outcome (3) 3
antimitotic agents (2) 2
antineoplastic agents (2) 2
bone marrow (2) 2
capecitabine (2) 2
chemoradiation (2) 2
chemotherapy, adjuvant (2) 2
clinical trials (2) 2
combination (2) 2
disease progression (2) 2
fluorouracil - administration & dosage (2) 2
germany (2) 2
iii trial (2) 2
infusions, intravenous (2) 2
kaplan-meier estimate (2) 2
medical informatics (2) 2
mrc cr07 (2) 2
neoadjuvant therapy - adverse effects (2) 2
neoadjuvant therapy - mortality (2) 2
oncology, experimental (2) 2
organoplatinum compounds - administration & dosage (2) 2
proportional hazards models (2) 2
radiotherapy (2) 2
rectal neoplasms - therapy (2) 2
surgery (2) 2
time factors (2) 2
abridged index medicus (1) 1
acute myelogenous leukemia (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - secondary (1) 1
adenocarcinoma - therapy (1) 1
adjuvant chemotherapy (1) 1
adjuvant treatment (1) 1
advanced follicular lymphoma (1) 1
age factors (1) 1
aged, 80 and over (1) 1
aml (1) 1
analysis (1) 1
antibiotics, antineoplastic - therapeutic use (1) 1
antibodies, monoclonal, murine-derived - administration & dosage (1) 1
antibodies, monoclonal, murine-derived - adverse effects (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols - administration & dosage (1) 1
b-cell (1) 1
bendamustine (1) 1
bendamustine hydrochloride (1) 1
biometry (1) 1
bone-marrow (1) 1
cancer therapies (1) 1
care and treatment (1) 1
chemoradiotherapy (1) 1
chemoradiotherapy, adjuvant - adverse effects (1) 1
chemoradiotherapy, adjuvant - mortality (1) 1
classification (1) 1
colon-cancer (1) 1
colorectal cancer (1) 1
comparative analysis (1) 1
cyclophosphamide (1) 1
cyclophosphamide - administration & dosage (1) 1
cyclophosphamide - adverse effects (1) 1
cytarabine (1) 1
cytarabine - therapeutic use (1) 1
daunorubicin - therapeutic use (1) 1
dose fractionation (1) 1
double-blind method (1) 1
doxorubicin - administration & dosage (1) 1
doxorubicin - adverse effects (1) 1
drug administration schedule (1) 1
drug therapy (1) 1
elderly-patients (1) 1
fees & charges (1) 1
flt3 mutations (1) 1
fluorouracil - therapeutic use (1) 1
follow-up (1) 1
hematology (1) 1
hematopoietic stem cell transplantation (1) 1
hypertension (1) 1
ii multicenter (1) 1
intention to treat analysis (1) 1
internal medicine (1) 1
leucovorin (1) 1
leukemia (1) 1
leukemia, myeloid, acute - diagnosis (1) 1
leukemia, myeloid, acute - drug therapy (1) 1
leukemia, myeloid, acute - mortality (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 7, pp. 679 - 687
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 979 - 989
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.